艾拉莫德对类风湿关节炎合并慢性间质性肺炎的近期临床疗效观察

目的 探讨艾拉莫德对类风湿关节炎(rheumatoid arthritis，RA)合并慢性间质性肺炎(interstitial pneumonia，IP)的近期临床疗效及安全性。方法 回顾性分析2012年3月—2013年5月17例RA合并慢性IP患者在常规治疗疗效不明显时，联合艾拉莫德治疗的近期临床疗效及安全性。结果 联合艾拉莫德治疗前ESR、CRP、RF、晨僵时间、DAS28评分均较高，联合艾拉莫德治疗后均有下降；经统计学分析，RF差异具有统计学意义(P<0.05)，CRP、ESR、晨僵时间、DAS28评分差异显著(P<0.01)；同时在联合艾拉莫德治疗后动脉血氧分压可得到明显改善(P<0.05)，肺部HRCT未见明显改变；血液系统WBC、HB、PLT无明显降低或升高。17例患者中有1例(5.9%)患者出现上腹部不适、1例(5.9%)出现肝功能轻度异常，无感染情况出现。结论 艾拉莫德对RA合并慢性IP患者具有确切的近期疗效，不良反应发生率低，合并感染情况少。

Short-term Effects of Rheumatoid Arthritis Complicated with Chronic Interstitial Pneumonia Treated by Iguratimod

OBJECTIVE To observe the short-term effects and safety of iguratimod on rheumatoid arthritis(RA) complicated with chronic interstitial pneumonia(IP). METHODS The short-term effects and safety of 17 RA patients complicated with chronic IP(from March.2012 to May.2009), whose effects were not satisfied treated by conventional treatment and treated by iguratimod united other drugs, were retrospectively analyzed. RESULTS The ESR, CRP, RF, time of morning stiffness, DAS28 scores of the patients before treated by iguratimod were higher than after treated, the differences of RF was significant(P<0.05), the differences of CRP, ESR, time of morning stiffness, DAS28 score were more significant(P<0.01). The arterial partial oxygen pressure of patients could be improved (P<0.05), the HRCT of lung had no obvious changes after treated; the WBC, HB, PLT had no obvious increase or decrease. Among those 17 patients, there was 1 case (5.9%) with upper abdominal discomfort, 1 case (5.9%) with mildly abnormal liver function, no infection occured. CONCLUSION Iguratimod has exactly short-term effect on RA combined with chronic IP, low incidence of adverse reactions and infection.